Scalable in silico Simulation of Transdermal Drug Permeability: Application of BIOiSIM Platform.
BIOiSIM
computational modeling
machine learning
transdermal absorption
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
03
2020
accepted:
07
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
31
3
2021
Statut:
epublish
Résumé
Transdermal drug delivery is gaining popularity as an alternative to traditional routes of administration. It can increase patient compliance because of its painless and noninvasive nature, aid compounds in bypassing presystemic metabolic effects, and reduce the likelihood of adverse effects through decreased systemic exposure. In silico physiological modeling is critical to predicting dermal exposure for a therapeutic and assessing the impact of different formulations on transdermal disposition. The present study aimed at developing a physiologically based transdermal platform, "BIOiSIM", that could be globally applied to a wide variety of compounds to predict their transdermal disposition. The platform integrates a 16-compartment model of compound pharmacokinetics and was used to simulate and predict drug exposure of three chemically and biologically distinct drug-like compounds. Machine learning optimization was composed of two components: exhaustive search algorithm (coarse-tuning) and descent (fine-tuning) integrated with the platform used to quantitatively determine parameters influencing pharmacokinetics (eg permeability, k The model successfully predicted drug exposure (AUC, C BIOiSIM marks a novel approach to in silico prediction that will enable leveraging of machine learning technology in the pharmaceutical space. The approach to model development outlined results in scalable, accurate models and enables the generation of large parameter/coefficient datasets from in vivo clinical data that can be used in future work to train quantitative structure activity relationship (QSAR) models for predicting likelihood of compound utility as a transdermally administered therapeutic.
Identifiants
pubmed: 32606600
doi: 10.2147/DDDT.S253064
pii: 253064
pmc: PMC7296558
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Nicotine
6M3C89ZY6R
Morphine
76I7G6D29C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2307-2317Informations de copyright
© 2020 Maharao et al.
Déclaration de conflit d'intérêts
All authors are affiliated with VeriSIM Life Inc. Dr Jyotika Varshney reports a patent WO/2019/104101 pending. The authors report no other conflict of interest in this work.
Références
Adv Drug Deliv Rev. 2003 Sep 12;55(9):1185-99
pubmed: 12954198
Nat Biotechnol. 2008 Nov;26(11):1261-8
pubmed: 18997767
J Pain Symptom Manage. 2013 Jul;46(1):65-75
pubmed: 23026548
J Pain Symptom Manage. 2009 May;37(5):913-7
pubmed: 19321297
Ann ICRP. 2002;32(3-4):5-265
pubmed: 14506981
J Pain Symptom Manage. 2008 Mar;35(3):314-20
pubmed: 18178369
J Pharmacokinet Biopharm. 1992 Dec;20(6):591-609
pubmed: 1302764
Clin Pharmacol Ther. 1991 Sep;50(3):286-93
pubmed: 1914363
CPT Pharmacometrics Syst Pharmacol. 2013 Jul 10;2:e55
pubmed: 23842098
Pharmaceutics. 2017 Sep 06;9(3):
pubmed: 28878145
J Pharm Sci. 2012 Jul;101(7):2584-95
pubmed: 22517028
Pharm Res. 2016 Jul;33(7):1602-14
pubmed: 26956458
J Clin Oncol. 2001 May 1;19(9):2542-54
pubmed: 11331334
Drug Metab Dispos. 2018 Nov;46(11):1466-1477
pubmed: 30115648
Br J Clin Pharmacol. 1985 Feb;19(2):239-47
pubmed: 3986082
Biopharm Drug Dispos. 2019 Jan;40(1):18-31
pubmed: 30520057
Clin Pharmacokinet. 2005;44(7):661-80
pubmed: 15966752
Drug Alcohol Depend. 2013 Aug 1;131(3):258-62
pubmed: 23246635
Br J Clin Pharmacol. 2017 Nov;83(11):2458-2473
pubmed: 28688108
J Neuroinflammation. 2019 Nov 6;16(1):204
pubmed: 31694670
J Anal Toxicol. 1998 Jul-Aug;22(4):261-4
pubmed: 9681326
Drug Metab Rev. 2020 May;52(2):283-298
pubmed: 32083960
Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84
pubmed: 9249929
Drug Deliv. 2006 May-Jun;13(3):175-87
pubmed: 16556569
Eur J Haematol. 2020 Oct;105(4):419-425
pubmed: 32497305
J Anal Toxicol. 1996 Oct;20(6):369-78
pubmed: 8889672
Biopharm Drug Dispos. 2017 Mar;38(2):139-154
pubmed: 27925249
AAPS PharmSciTech. 2019 Jul 24;20(7):264
pubmed: 31342293
J Pain Palliat Care Pharmacother. 2005;19(4):39-44
pubmed: 16431831
Clin Drug Investig. 2009;29 Suppl 1:41-6
pubmed: 19445554
Br J Clin Pharmacol. 1994 Jun;37(6):571-6
pubmed: 7917776
SAR QSAR Environ Res. 2018 Nov;29(11):875-893
pubmed: 30286617
Handb Exp Pharmacol. 2009;(192):29-60
pubmed: 19184645
Arch Med Sci. 2019 Jan;15(1):146-151
pubmed: 30697265
CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531
pubmed: 27653238